报价延迟最少15分钟:2025/07/22 12:33 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
10.14 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-3.85/-1.63
|
|
企业价值
1.17B
|
| 资产负债 |
|
每股账面净值
2.50
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
23.68M
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/07/22 12:33 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States. |
